PTC Just Bought a Gene Therapy Out of Bankruptcy. It Might Be Brilliant.
PTC Therapeutics just scooped up a near-approval Fabry disease gene therapy from Sangamo's bankruptcy auction for $211 million. It's either the deal of the year or a cautionary tale waiting to happen.
Bargain Hunting in Biotech's Clearance Aisle
Imagine finding a nearly finished house at a foreclosure auction. The foundation is solid, the wiring is done, and somebody already passed most of the inspections. All you have to do is hang the curtains and move in. That's roughly what PTC Therapeutics just pulled off, except the "house" is a gene therapy for a rare genetic disease, and the "auction" was a federal bankruptcy court.
PTC won the bidding war for isaralgagene civaparvovec (ST-920), Sangamo Therapeutics' Fabry disease gene therapy, paying $111 million in cash at closing. If the therapy gets approved by the FDA, PTC owes up to $100 million more in milestone payments. Total potential price tag: $211 million.
That might sound like a lot. But for a therapy that's already in the middle of a rolling FDA submission, it's the biotech equivalent of buying a sports car at government-seizure prices.
What Went Wrong at Sangamo
Sangamo didn't go bankrupt because its science was bad. It went bankrupt because the money ran out before the finish line.
The timeline tells the story. In April 2025, Nasdaq warned Sangamo that its stock price had fallen below the exchange's minimum threshold. By mid-June, the board approved a restructuring and slashed the workforce. One week later, on June 23, 2026, Sangamo filed for Chapter 11 bankruptcy protection.
The filing kicked off a court-supervised auction process designed to squeeze as much value as possible out of Sangamo's remaining assets. Eli Lilly picked up some of the company's other platforms. And the crown jewel, the Fabry gene therapy, went to PTC after a competitive auction that also attracted bids from Astellas and TerSera.
It's a familiar tragedy in biotech: a company builds something genuinely promising, burns through its cash reserves getting it to the doorstep of approval, and then has to sell the whole thing at a discount because there's nothing left in the bank account. The science worked. The balance sheet didn't.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
This isn't some early-stage moonshot that might pay off in a decade. ST-920 is shockingly close to the finish line.
Sangamo started a rolling BLA submission (basically filing the application for FDA approval in installments) back in December 2025. PTC expects to complete that submission by the end of 2026. If things go smoothly, the company says it could launch the therapy as early as 2027.
The clinical data backing it up is solid. In the Phase 1/2 STAAR study, all 32 patients who received the therapy showed a positive eGFR slope at 52 weeks, which is a measure of kidney function that the FDA agreed could serve as the primary basis for accelerated approval. In the 19 patients with longer follow-up, that benefit held at 104 weeks. The longest-treated patient has shown sustained enzyme activity out to 4.5 years.
The therapy also carries a stack of FDA designations: Orphan Drug, Fast Track, and RMAT (Regenerative Medicine Advanced Therapy). Those aren't guarantees of approval, but they're the regulatory equivalent of cutting to the front of the line.
Why Fabry Disease Is Worth Fighting For
Fabry disease is a rare genetic condition where the body can't produce enough of an enzyme called alpha-galactosidase A. Without it, fatty substances build up in cells throughout the body, damaging the kidneys, heart, and nervous system. It's a slow, painful process.
The current standard of care is enzyme replacement therapy (ERT): biweekly infusions that supplement the missing enzyme. Products like Fabrazyme, Replagal, and the newer Elfabrio dominate the market. There's also migalastat, an oral option for certain patients.
The global Fabry treatment market is worth an estimated $2.6 to $2.8 billion in 2026. That's a meaningful commercial opportunity, and it's why gene therapy developers have been circling.
The promise of a gene therapy like ST-920 is simple: instead of showing up every two weeks for an infusion for the rest of your life, you get one treatment that teaches your body to make the missing enzyme on its own. If the durability data holds up (and 4.5 years of enzyme activity in the longest-treated patient is encouraging), it could fundamentally change how Fabry disease is managed.
PTC isn't the only company chasing this idea. 4D Molecular Therapeutics has its own Fabry gene therapy program (4D-310), and Freeline is developing FLT190. But none of these competitors appear to be as close to FDA approval as ST-920 is right now.
PTC's Playbook: Buy Smart, Launch Fast
This deal makes strategic sense for PTC because the company already has the infrastructure to sell rare disease therapies globally. It markets multiple products, including a treatment for PKU, through a commercial network that spans dozens of countries.
Adding a Fabry gene therapy to that existing platform is like a restaurant adding a new dish to the menu: the kitchen, the staff, and the customers are already there. PTC doesn't need to build anything from scratch.
Financially, PTC is in a position to make this bet. The company monetized its Evrysdi royalties, giving it a war chest for exactly these kinds of opportunistic acquisitions. Management has signaled it's targeting cash flow break-even in 2026, which means the company isn't burning through reserves at a scary rate.
The milestone structure is also clever. PTC pays $111 million upfront, which is real money but not bet-the-farm money for a company of its size. The additional $80 million only comes due if ST-920 wins accelerated approval, and the final $20 million triggers on traditional (full) approval. If the FDA says no, PTC's total exposure is limited to the upfront payment.
The Risks Are Real
Let's not pretend this is a slam dunk. Gene therapy has a long history of promising early data that doesn't translate into commercial success. Manufacturing is notoriously complex and expensive. And "near-approval" is not the same as "approved."
The FDA could ask for more data. The rolling BLA could hit a snag. Competing therapies could catch up. The commercial ramp could be slower than expected in a market where doctors and patients are accustomed to established ERT options.
There's also the broader context: Sangamo's bankruptcy is a reminder that the gene therapy sector is under real financial stress. Multiple companies have struggled to turn scientific breakthroughs into sustainable businesses. PTC is betting it can succeed where Sangamo stumbled, but it's inheriting a program from a company that couldn't make the economics work.
The Bottom Line
PTC Therapeutics just bought a nearly finished gene therapy at a bankruptcy discount, with a clear path to FDA submission by year-end and a potential launch in 2027. The Fabry market is worth nearly $3 billion and ripe for disruption by a one-time treatment. The deal structure limits PTC's downside while preserving massive upside if the therapy gets across the finish line.
It's the kind of move that looks either genius or reckless, depending entirely on what the FDA decides. For now, the smart money says PTC got a steal. But in biotech, the last mile is always the hardest.
Clinical & Regulatory6 min read
The Vaccine That Got Killed by Fear Is Back From the Dead
The last Lyme disease vaccine was killed by lawsuits, not science. Now Pfizer and Valneva's new candidate just hit a major regulatory milestone in Europe, and this time the stakes (and the tick populations) are much bigger.
